Low Vitamin D Tied to Bone Loss in Breast Cancer

2006 ◽  
Vol 39 (15) ◽  
pp. 29
Author(s):  
JANE SALODOF MACNEIL
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Bone Loss

scholarly journals Bisphosphonates and the prevention of osteoporosis in the adjuvant setting

2005 ◽  
Vol 8 (11) ◽  
Author(s):  
Michael Gnant
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Vitamin D ◽  
Bone Loss ◽  
Bisphosphonate Treatment ◽  
Breast Cancer Patients ◽  
Adjuvant Setting ◽  
Mineral Density ◽  
Prevention Of Osteoporosis

Endocrine adjuvant therapy for breast cancer has been associated with a decrease in bone mineral density (BMD) and bone loss. For aromatase inhibitors, this bone loss is likely to be the most significant limitation to their long-term use. Treatments traditionally used to counteract his effect include exercise and supplementation with calcium and vitamin D. A newer treatment is the use of bisphosphonates, a class of drugs that reduce osteoclast activity. Clinical trials currently underway to examine the effect of bisphosphonate treatment on breast cancer patients have shown improvement in bone strength. Additional benefits of bisphosphonates, currently under study, give this class of drugs an important role to play in the treatment of cancer treatment-induced bone loss.

Less Bone Loss in Breast Cancer With Vitamin D

2011 ◽  
Vol 41 (13) ◽  
pp. 40
Author(s):  
RICHARD HYER
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Bone Loss

Prevalence of Secondary Causes of Bone Loss Among Breast Cancer Patients With Osteopenia and Osteoporosis

2008 ◽  
Vol 26 (33) ◽  
pp. 5380-5385 ◽  
Author(s):  
Pauline M. Camacho ◽  
Amit S. Dayal ◽  
Josefina L. Diaz ◽  
Fadi A. Nabhan ◽  
Monica Agarwal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Bone Loss ◽  
Comprehensive Evaluation ◽  
Health Clinic ◽  
Idiopathic Hypercalciuria ◽  
Breast Cancer Patients ◽  
Cancer Group ◽  
Breast Cancer Group ◽  
Secondary Causes

PurposeTo determine the prevalence of secondary causes of bone loss among patients with breast cancer with osteopenia and osteoporosis.Patients and MethodsAll women referred to a bone health clinic over a 6-year period for bone evaluation were included in this retrospective study and stratified based on presence or absence of a breast cancer history. The prevalence of secondary causes of bone loss in the two groups was compared.ResultsOf the 238 women identified, 64 women had breast cancer. The non–breast cancer group (n = 174) was significantly older (P = .015), had a lower mean weight (P = .019), lower 25 hydroxy-vitamin D level (P = .019), and greater degree of bone loss in both the spine and hip (P < .001 and 0.004, respectively). The presence of at least one secondary cause of bone loss, excluding cancer-related therapies, was seen in 78% of the breast cancer patient group and in 77% of the non–breast cancer group (P = not significant). Newly diagnosed metabolic bone disorders were seen in 58% of the breast cancer population. The most common was vitamin D deficiency, seen in 38% of patients in the breast cancer group and 51% of patients in the non–breast cancer group. Idiopathic hypercalciuria was diagnosed in 15.6%, primary hyperparathyroidism in 1.6%, and normocalcemic hyperparathyroidism in 3.1% of the breast cancer population.ConclusionA high prevalence of secondary causes of bone loss among patients with breast cancer supports a comprehensive evaluation in these patients, particularly those considering therapy with an aromatase inhibitor.

Vitamin D repletion and prevention of bone loss in nonosteoporotic women with breast cancer.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 9026-9026
Author(s):  
S. Servitja ◽  
D. Prieto-Alhambra ◽  
M. Martinez-Garcia ◽  
L. Garrigos ◽  
M. J. Pena ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Bone Loss ◽  
Prevention Of Bone Loss

A phase II RCT of high-dose vitamin D supplementation and exercise for cancer treatment-induced bone loss in breast cancer patients on aromatase inhibitors.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 11500-11500
Author(s):  
Luke Joseph Peppone ◽  
Jennifer E Reschke ◽  
Michelle Christine Janelsins ◽  
Julia Ellen Inglis ◽  
Karen Michelle Mustian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Bone Loss ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Phase Ii ◽  
Aromatase Inhibitors ◽  
High Dose ◽  
Breast Cancer Patients ◽  
Hip Bmd

11500 Background: Cancer-treatment-induced bone loss (CTIBL) is a side effect of aromatase inhibitors (AIs) and can result in osteoporotic fractures. Vitamin D (VITD) protects against postmenopausal bone loss but it is unclear if the recommended daily allowance (RDA: 600 IU/day) of VITD is sufficient to prevent CTIBL. This phase II RCT aimed to assess the feasibility, safety, and preliminary efficacy of high-dose VITD (with and without exercise) on bone mineral density (BMD) compared to the RDA. Methods: Non-metastatic breast cancer patients starting AIs with low VITD (<32 ng/ml) were randomized 1:1:1 into 3 arms: 1) placebo 2) high-dose VITD (50,000 IU/week) or 3) high-dose VITD + Exercise for Cancer Patients (EXCAP): a home-based, personalized walking and resistance band training program for 24 weeks. All subjects received the RDA of VITD 600 IU/day. Serum VITD and calcium levels were assessed at baseline, weeks 6, 12, 18, and 24. BMD was assessed at the hip via DXA at baseline and week 24. Results: Of the 116 subjects randomized (mean age = 60; 94% white; mean baseline VITD = 24.6 ng/mL), 90 provided fully evaluable data. Compliance (≥ 80% of instructed doses) exceeded 95% in all 3 arms with no between-group difference. ANCOVA showed significant differences between groups on final VITD levels (high-dose = 63.6 vs high-dose + EXCAP = 60.3 vs placebo = 32.0 ng/mL; p<0.001) without severe calcium toxicities, as indicated by final calcium level (high-dose = 9.4 vs high-dose + EXCAP = 9.5 vs placebo = 9.4 ng/mL; p = 0.78). The placebo group lost a significant amount of hip BMD (−1.7%; p < 0.01) while hip BMD was maintained in the high-dose (−0.1%; p = 0.77) and high-dose + EXCAP (−0.2%; p = 0.74) resulting in significant between-group differences for high-dose + EXCAP vs placebo (p = 0.04) and high-dose vs placebo (p = 0.05). Conclusions: This is one of the first studies to show our novel high-dose VITD intervention, with and without exercise, significantly reduced hip BMD loss in breast cancer patients on AIs. Moreover, high-dose VITD supplementation is safe and feasible in this population. A phase III RCT is needed to confirm these findings. Funding: K07CA168911. Clinical trial information: NCT01419730.

Low Vitamin D Tied to Bone Loss in Breast Cancer

2006 ◽  
Vol 36 (14) ◽  
pp. 40
Author(s):  
JANE SALODOF MACNEIL
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Bone Loss

Vitamin D deficiency: A threat to bone health in breast cancer patients during adjuvant treatment with aromatase inhibitors

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 554-554 ◽  
Author(s):  
P. Lonning ◽  
J. Geisler ◽  
L. E. Krag ◽  
E. Løkkevik ◽  
T. Risberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Placebo Group ◽  
Bone Loss ◽  
Femoral Neck ◽  
Vitamin D Deficiency ◽  
Postmenopausal Women ◽  
Breast Cancer Patients ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

554 Background: To evaluate potential detrimental effects of the aromatase inactivator exemestane on bone, 147 postmenopausal women with early breast cancer were randomised to receive either exemestane for 2 years or placebo (J. Clin. Oncol. 23 [22], 5126–5137, 2005). Exemestane increased the annual bone loss from the femoral neck (2.72%) compared to placebo (1.48%; P = 0.024) with a non-significant increase in the lumbar spine (exemestane 2.17% versus placebo 1.84%). The annual bone loss was higher than expected in the placebo arm. Methods: Various biomarkers involved in bone metabolism (25-hydroxyvitamin D, parathormone, calcium, estrogens, androgens) were analysed to elucidate their influence on bone status at baseline and BMD loss during treatment with exemestane compared to placebo. Results: Using a cut-off value of 30 ng/ml for 25-hydroxyvitamin D (J. Clin. Endocrinol. Metab. 90 [6], 3800–3801, 2005), the majority of study participants suffered from vitamin D deficiency (56 of 62 patients in the placebo group and 52 of 59 in the exemestane group). The mean levels (95% confidence interval) of vitamin D were 22.6 ng/ml (21.2 - 24.1) in the placebo group and 21.6 ng/ml (20.0 - 23.3) in the treatment group, revealing no differences between these groups. Low serum calcium levels at baseline were found to be significantly correlated to low BMD in the femoral neck in the exemestane group. However, individual levels of vitamin D, parathormone and estradiol at baseline were not correlated significantly to BMD. Conclusions: Considering an annual bone loss of 0.5% to be representative for postmenopausal women (Osteoporos. Int. 15, 881–886, 2004), our data indicate that vitamin D deficiency could be the most important factor elevating bone loss among patients treated with exemestane as well as in the placebo group. These findings, together with the observation of a moderate additional effect of exemestane on bone loss, underlines the need for proper vitamin D substitution of postmenopausal women in general and in breast cancer patients during treatment with aromatase inhibitors in particular. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document